Overview

Biopharmaceutical Contract Manufacturing Market is estimated to value over USD 23.9 billion by 2027 end with a CAGR of over 5.5% during the forecast period 2020 to 2027

With the increasing expansion of the biopharmaceutical industry, many manufacturers are facing multiple problems like dearth of expertise and systematic equipment during in-house manufacturing. The availability of external funding and biotech manufacturing has led to a spurt of bio companies in early stage as they are the primary CMO customers due to their lack of capability of developing vigorous manufacturing operations. Multiple established CMOs like Lonza and Boehringer Ingelheim have received competition from many emerging CMOs in this high-volume market. For example, Samsung entered this market as Samsung Biologics in 2013 and has since expanded their bioreactor capacities to witness growth in this sector. The company currently owns three plants with over 360,000 litres of capacity and the fourth plant is under assessment, which shall be located outside South Korea. Additionally, technological breakthroughs in bioprocessing have been crucial in the development of CMOs by working on issues like need of a batch-wise changeover and high production costs. Bioprocessing systems that can use once have proven to be significant in reducing the total scale-up and production costs. With strategic acquisitions and mergers, the biopharmaceutical contract manufacturing market growth is expected to grow substantially over the forecasted timeframe. However, established companies consider outsourcing as unfeasible owing to limited management oversight and loss of strategic control, resulting in these companies choosing in-house manufacturing operations.

Market Segmentation:

By Source
• Mammalian Source
• Non-Mammalian Source
By Product
• Biosimilars
• Biologics
o Monoclonal antibodies (MABs)
o Recombinant Proteins
o Vaccines
o Antisense, RNAi, & Molecular Therapy
o Others
By Services
• Product Development
o Downstream
o Upstream
• Fill and Finish Operations
• Analytical and QC Testing
• Packaging
By Region
•   North America
•   Latin America
•   Europe
•   Middle East and Africa

The market is categorised into source, product, services and region. The source segment is diversified into mammalian source and mon-mammalian source. The mammalian contract manufacturing segment is anticipated to hold the largest biopharmaceutical contract manufacturing market share, and this can be credited to increased acceptance rate of mammalian system for producing biologics. Furthermore, most of the biopharma products currently in the pipeline are expressed by mammalian source. Companies like Charles River and Lonza have heavily invested in expanding their manufacturing facilities of mammalian cell culture for biosimilars and biologics. The product segment is classified into biosimilars and biologics. The biologics segment dominated the market in 2018 and this primarily owing to the massive commercial acceptance of biologics by the market. The service segment is fragmented into process development, fill and finish operations, analytical and QC testing and packaging.

Regional Analysis:

The North America region subjugated the market in 2017 owing to a strong presence of biopharma facilities in the Unites States along with increased research and development activities in biopharma sector. The Asia Pacific region, however, shall grow at a significant rate during the forecast period and this is due to low operating and manufacturing costs provided by countries like India.

Competitive Landscape:

The major market players associated are
• Boehringer Ingelheim GmbH
• Lonza
• Inno Biologics Sdn Bhd
• Rentschler Biotechnologie GmbH
• JRS Pharma
• AGC Biologics
• ProBioGen
• Fujifilm Diosynth Biotechnologies U.S.A., Inc.
• Toyobo Co., Ltd.
• Samsung BioLogics
• Thermo Fisher Scientific, Inc.
• Binex Co., Ltd.
• WuXi Biologics
• AbbVie, Inc.

FutureWise Key Takeaways:

•   Growth prospects
•   SWOT analysis
•   Key market trends
•   Key data-points affecting market growth

Objectives of the Study:

•   To provide with an exhaustive analysis on the global biopharmaceutical contract manufacturing market by source, by product, by services and by region
•   To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•   To evaluate and forecast micro-markets and the overall market
•   To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•   To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com